Biomaterial Database

[Tiagabine--own experience in the refractory epilepsy treatment]. 2013

Barbara Błaszczyk

Wydział Nauk o Zdrowiu WSEiP, Kielce. barbarablaszczyk@op.pl

Tiagabine belongs to a new generation of antiepileptic drugs with a unique mechanism of action. It is well-absorbable from the gastrointestinal tract, has a linear pharmacokinetics, does not affect cognitive function and it interacts poorly with other antiepileptic drugs. Tiagabine is recommended for adults and children past 12 years of age with epilepsy, suffering from partial seizures, with and without secondary generalization. Following the period of a great enthusiasm as to the use of tiagabine, it was put aside, though unfairly, according to the author's own studies as well as the reports in current literature, it still has its place in the treatment of drug-resistant epilepsy.

UI	MeSH Term	Description	Entries
D009557	Nipecotic Acids		Acids, Nipecotic
D011307	Drug Prescriptions	Directions written for the obtaining and use of DRUGS.	Drug Prescribing,Drug Prescription,Drug Prescribings,Prescribing, Drug,Prescribings, Drug
D002648	Child	A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL.	Children
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D003071	Cognition	Intellectual or mental process whereby an organism obtains knowledge.	Cognitive Function,Cognitions,Cognitive Functions,Function, Cognitive,Functions, Cognitive
D004827	Epilepsy	A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313)	Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078308	Tiagabine	A nipecotic acid derivative that acts as a GABA uptake inhibitor and anticonvulsant agent. It is used in the treatment of EPILEPSY, for refractory PARTIAL SEIZURES.	(R)-(4,4-bis(3-Methyl-2-thienyl)-3-butenyl)-3-piperidinecarboxylic acid, Hydrochloride,Gabitril,N-(4,4-di(3-Methylthien-2-yl)but-3-enyl)nipecotic acid,NO 328,NO 329,NO-328,NO-329,Tiagabine Hydrochloride,Tiagabine, (S)-isomer
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D000927	Anticonvulsants	Drugs used to prevent SEIZURES or reduce their severity.	Anticonvulsant,Anticonvulsant Drug,Anticonvulsive Agent,Anticonvulsive Drug,Antiepileptic,Antiepileptic Agent,Antiepileptic Agents,Antiepileptic Drug,Anticonvulsant Drugs,Anticonvulsive Agents,Anticonvulsive Drugs,Antiepileptic Drugs,Antiepileptics,Agent, Anticonvulsive,Agent, Antiepileptic,Agents, Anticonvulsive,Agents, Antiepileptic,Drug, Anticonvulsant,Drug, Anticonvulsive,Drug, Antiepileptic,Drugs, Anticonvulsant,Drugs, Anticonvulsive,Drugs, Antiepileptic